Nektar prices $325M upsized equity offering at $92/share; net proceeds ~$350.9M

NEKTAR THERAPEUTICS

Firm shares: 3,532,609 at $92.00; underwriters exercised option for 529,891 additional shares in full.
Net proceeds estimated at ~$350.9M after underwriting discounts and offering expenses.
Proceeds to fund general corporate purposes, including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata.
Joint bookrunners include Jefferies, TD Cowen, Piper Sandler; Citigroup also bookrunner.
Offering expected to close on April 23, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NEKTAR THERAPEUTICS entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. valued at approximately $350.9 million (effective 2026-04-21).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co.
Value: approximately $350.9 million
Effective: 2026-04-21

Exact text from the filing

On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 3,532,609 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”) at a price to the public of $92.00 per Firm Share, less underwriting discounts and commissions.

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001193125-26-171731

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.